Clozapine induces astrocyte-dependent FDG-PET hypometabolism

Purpose Advances in functional imaging allowed us to visualize brain glucose metabolism in vivo and non-invasively with [ 18 F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) imaging. In the past decades, FDG-PET has been instrumental in the understanding of brain function in health a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of nuclear medicine and molecular imaging 2022-06, Vol.49 (7), p.2251-2264
Hauptverfasser: Rocha, Andréia, Bellaver, Bruna, Souza, Débora G., Schu, Guilherme, Fontana, Igor C., Venturin, Gianina T., Greggio, Samuel, Fontella, Fernanda U., Schiavenin, Manoela L., Machado, Luiza S., Miron, Diogo, da Costa, Jaderson C., Rosa-Neto, Pedro, Souza, Diogo O., Pellerin, Luc, Zimmer, Eduardo R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose Advances in functional imaging allowed us to visualize brain glucose metabolism in vivo and non-invasively with [ 18 F]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) imaging. In the past decades, FDG-PET has been instrumental in the understanding of brain function in health and disease. The source of the FDG-PET signal has been attributed to neuronal uptake, with hypometabolism being considered as a direct index of neuronal dysfunction or death. However, other brain cells are also metabolically active, including astrocytes. Based on the astrocyte-neuron lactate shuttle hypothesis, the activation of the glutamate transporter 1 (GLT-1) acts as a trigger for glucose uptake by astrocytes. With this in mind, we investigated glucose utilization changes after pharmacologically downregulating GLT-1 with clozapine (CLO), an anti-psychotic drug. Methods Adult male Wistar rats (control, n  = 14; CLO, n  = 12) received CLO (25/35 mg kg −1 ) for 6 weeks. CLO effects were evaluated in vivo with FDG-PET and cortical tissue was used to evaluate glutamate uptake and GLT-1 and GLAST levels. CLO treatment effects were also assessed in cortical astrocyte cultures (glucose and glutamate uptake, GLT-1 and GLAST levels) and in cortical neuronal cultures (glucose uptake). Results CLO markedly reduced in vivo brain glucose metabolism in several brain areas, especially in the cortex. Ex vivo analyses demonstrated decreased cortical glutamate transport along with GLT-1 mRNA and protein downregulation. In astrocyte cultures, CLO decreased GLT-1 density as well as glutamate and glucose uptake. By contrast, in cortical neuronal cultures, CLO did not affect glucose uptake. Conclusion This work provides in vivo demonstration that GLT-1 downregulation induces astrocyte-dependent cortical FDG-PET hypometabolism—mimicking the hypometabolic signature seen in people developing dementia—and adds further evidence that astrocytes are key contributors of the FDG-PET signal.
ISSN:1619-7070
1619-7089
1619-7089
DOI:10.1007/s00259-022-05682-3